Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV

No abstract is available for this paper.

• Publication year

  2017

• Venue

  AIDS (London)

• Publication date

  2017-03-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/QAD.0000000000001427PMID 28252528PMCID PMC5382495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy

  2016cited by this paper
• Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy

  2016cited by this paper
• Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV

  2016cited by this paper
• Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals.

  2016cited by this paper
• Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy.

  2015cited by this paper
• Rosuvastatin Reduces Vascular Inflammation and T-cell and Monocyte Activation in HIV-Infected Subjects on Antiretroviral Therapy

  2015cited by this paper
• Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation

  2015cited by this paper
• Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.

  2015cited by this paper
• Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection.

  2015cited by this paper
• Lack of Pharmacokinetic Interactions Between Pitavastatin and Efavirenz or Darunavir/Ritonavir

  2014cited by this paper
• Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy.

  2014cited by this paper
• Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy.

  2014cited by this paper
• Pitavastatin is a potent anti-inflammatory agent in the rat paw model of acute inflammation.

  2014cited by this paper
• Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients

  2014cited by this paper
• Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients.

  2014cited by this paper
• HIV infection and the risk of acute myocardial infarction.

  2013cited by this paper
• Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors

  2013cited by this paper
• Arterial inflammation in patients with HIV.

  2012cited by this paper
• High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial.

  2011cited by this paper
• Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients.

  2011cited by this paper
• The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia

  2011cited by this paper
• Plasma levels of soluble CD14 independently predict mortality in HIV infection.

  2011cited by this paper
• Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

  2010cited by this paper
• Effects of Statins on Adipose Tissue Inflammation: Their Inhibitory Effect on MyD88-Independent IRF3/IFN-&bgr; Pathway in Macrophages

  2008cited by this paper
• Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation.

  2007cited by this paper
• The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis.

  2006cited by this paper
• Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects.

  2005cited by this paper
• APOPTOSIS IN HUMAN MONOCYTE‐MACROPHAGES EXPOSED TO OXIDIZED LOW DENSITY LIPOPROTEIN

  1996cited by this paper

• The heart and HIV therapy: exploring the dual cardiovascular impact of antiretroviral treatment – a narrative review

  2025cites this paper
• Impact of Intestinal Parasitic Infections on Gut Epithelial Barrier and Inflammation among Foreign-Born Persons Living with HIV.

  2025cites this paper
• Dyslipidemia and statin use in people with HIV-1 infection: beyond the lipid-lowering effect.

  2025cites this paper
• Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel.

  2025cites this paper
• HIV and the gut: implications for HIV persistence, immune dysfunction and cure strategies

  2025cites this paper
• Atherosclerosis and HIV: Exploring Cardiovascular Risks and Management.

  2024cites this paper
• Effects of statins beyond lipid-lowering agents in ART-treated HIV infection

  2024cites this paper
• Pitavastatin attenuates hypercholesterolemia-induced decline in serotonin transporter availability

  2024cites this paper
• Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease

  2024cites this paper
• Letter to editor: Prophylactic use of statins in HIV patients: Better be safe than sorry

  2024cites this paper
• Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the Week.

  2023cites this paper
• Pitavastatina como estatina de escolha para o controle da dislipidemia em pacientes infectados pelo HIV em uso de antirretrovirais

  2023cites this paper
• Pharmacological and Behavioral Interventions to Mitigate Premature Aging in Patients with HIV

  2023cites this paper
• The Impact of Contemporary Antiretroviral Drugs on Atherosclerosis and Its Complications in People Living With HIV: A Systematic Review

  2023cites this paper
• Can statin preventative treatment inform geroscience‐guided therapeutics?

  2023cites this paper
• A deeper dive into the REPRIEVE trial and the potential role of inflammation in residual risk.

  2023cites this paper
• Correlation of human immunodeficiency virus and antiretroviral therapy with cardiac disorders

  2023cites this paper
• Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.

  2023cites this paper
• Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study

  2023cites this paper
• Atorvastatin attenuates allergic inflammation by blocking prostaglandin biosynthesis in rats with allergic rhinitis.

  2023cites this paper
• Factors Associated with Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People with HIV on Antiretroviral Therapy.

  2022cites this paper
• Cardiovascular Disease and Thrombosis in HIV Infection

  2022cites this paper
• Effectiveness and safety of statins on outcomes in patients with HIV infection: a systematic review and meta-analysis

  2022cites this paper
• Addressing gaps in cardiovascular care for people with HIV: bridging scientific evidence and practice

  2022cites this paper
• Statins for primary cardiovascular disease prevention among people with HIV: emergent directions

  2022cites this paper
• Lp-PLA2 as a biomarker and its possible associations with SARS-CoV-2 infection

  2022cites this paper
• Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis

  2021cites this paper
• Cost‐effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States

  2021influential citation
• Probing the Interface of HIV and Inflammaging

  2021cites this paper
• Lack of Atorvastatin Effect on Monocyte Gene Expression and Inflammatory Markers in HIV-1-infected ART-suppressed Individuals at Risk of non-AIDS Comorbidities

  2021cites this paper
• Human Immunodeficiency Virus Persistence in the Spleen: Opportunities for Pharmacologic Intervention

  2021cites this paper
• New Pharmacological Tools to Target Leukocyte Trafficking in Lung Disease

  2021cites this paper
• The Effect of Rosuvastatin on Plasma/Serum Levels of High-Sensitivity C-Reactive Protein, Interleukin-6, and D-Dimer in People Living with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis

  2021cites this paper
• PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

  2021cites this paper
• Myocardial ischemia and left ventricular diastolic dysfunction in HIV infected patients and asymptomatic for coronary artery disease

  2021cites this paper
• The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• A comprehensive review on the lipid and pleiotropic effects of pitavastatin.

  2021cites this paper
• Contribution of Adipose Tissue to the Chronic Immune Activation and Inflammation Associated With HIV Infection and Its Treatment

  2021cites this paper
• Differential Plasma Protein Regulation and Statin Effects in HIV-infected and Non-HIV-infected Patients Utilizing a Proteomics Approach Protein Regulation and Statin Effects in HIV.

  2020cites this paper
• Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection

  2020cites this paper
• Epidemiology, pathophysiology, and prevention of heart failure in people with HIV.

  2020cites this paper
• Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost‐effectiveness analysis

  2020cites this paper
• Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy

  2020cites this paper
• The Impact of Moderate or High-Intensity Combined Exercise on Systemic Inflammation among Older Persons with and without HIV.

  2020cites this paper
• Protocol for systematic review and meta-analysis: impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases

  2020cites this paper
• A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV

  2020cites this paper
• Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome

  2020cites this paper
• Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV

  2020cites this paper
• Managing HIV‐associated inflammation and ageing in the era of modern ART

  2020cites this paper
• Impact of HIV infection on aging and immune status

  2020cites this paper
• Effect of Statin Use on Inflammation and Immune Activation Biomarkers in HIV-Infected Persons on Effective Antiretroviral Therapy

  2020cites this paper
• HIV and Dyslipidemia

  2020cites this paper
• Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association.

  2019cites this paper
• Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients.

  2019cites this paper
• Mechanisms of Cardiovascular Disease in the Setting of HIV Infection.

  2019cites this paper
• Lipid Abnormalities in Persons Living With HIV Infection.

  2019cites this paper
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

  2019cites this paper
• Observation of the clinical effects of Danhong injections combined with pitavastatin on blood lipid regulation in patients with ischemic strokes complicated with lipid abnormalities

  2019cites this paper
• Specific Biological Features of Adipose Tissue, and Their Impact on HIV Persistence

  2019cites this paper
• Association of Statin Use with Kidney Damage and Function Among HIV-infected Men

  2019cites this paper
• No Evidence for an Association between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART

  2019cites this paper
• Conceptualizing the Risks of Coronary Heart Disease and Heart Failure Among People Aging with HIV: Sex-Specific Considerations

  2019cites this paper
• Immune activation and inflammation in people with HIV:  Challenging targets.

  2019cites this paper
• Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection

  2019cites this paper
• HIV infection and coronary heart disease: mechanisms and management

  2019cites this paper
• AHA SCIENTIFIC STATEMENT Characteristics , Prevention , and Management of Cardiovascular Disease in People Living With HIV A Scientific Statement From the American Heart Association Circulation

  2019cites this paper
• Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

  2019cites this paper
• Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.

  2019cites this paper
• Escore de cálcio coronário na estratificação do risco cardiovascular de portadores de HIV/AIDS em tratamento

  2019cites this paper
• Polypharmacy in HIV: recent insights and future directions.

  2019cites this paper
• NOVEL MECHANISMS AND ANTI-INFLAMMATORY STRATEGIES TO REDUCE CARDIOVASCULAR RISK IN HUMAN IMMUNODEFICIENCY VIRUS.

  2018cites this paper
• Novel mediators of statin effects on plaque in HIV: a proteomics approach

  2018cites this paper
• Measurement of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in the Assessment of Cardiovascular Risk

  2018cites this paper
• Sex Differences in HIV Infection

  2018cites this paper
• Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals

  2018cites this paper
• A Randomized, Double-Blinded, Placebo-Controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed HIV Infection.

  2018cites this paper
• Anti-inflammatory therapy in well controlled HIV infection.

  2018cites this paper
• Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial

  2018cites this paper
• Benefits and Risks of Statin Therapy in the HIV-Infected Population

  2018cites this paper
• Epidemiology of ischemic heart disease in HIV

  2017cites this paper
• Pitavastatin for lowering lipids.

  2017cites this paper
• Cardiovascular disease risk among women living with HIV in North America and Europe

  2017cites this paper
• Statin Prescribing Practices in the Comprehensive Care for HIV-Infected Patients

  2017cites this paper
• Another statin option in HIV.

  2017cites this paper
• Steven Grinspoon and Udo Hoffmann Reduction Cardiovascular Disease Imaging in HIV : Novel Phenotypes and New Targets for Risk

  2017cites this paper
• Cardiovascular Disease Imaging in HIV: Novel Phenotypes and New Targets for Risk Reduction.

  2017cites this paper
• Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation

  2017cites this paper